ProteLight Pharma announced that its independently developed China’s first Class 1 innovative granulin-class antimicrobial peptide drug, Puyike® (Peleganan Spray), received approval for market launch from the National Medical Products Administration (NMPA) on June 17, 2026. The drug is primarily indicated for the treatment of secondary wound infections such as burns and scalds.

Peleganan Spray is a First-in-class (FIC) new drug independently developed based on ProteLight Pharma’s Antimicrobial Peptide Drug Design Platform (AMPDDP). The successful approval marks the global debut of the first granulin-class anti-infective therapeutic.

The approval of Peleganan Spray for treating secondary wound infections including burns and scalds is supported by data from multiple pivotal clinical studies.

Efung Capital participated in ProteLight Pharma’s financing round in 2025. Looking ahead, Efung Capital will leverage its professional investment expertise and ecosystem empowerment capabilities in the biopharmaceutical sector to continue supporting ProteLight Pharma’s growth, actively facilitating the global development and commercialization of the company’s antimicrobial peptide innovative drug pipeline, and helping China-originated innovative drugs reach the world stage, bringing more Chinese solutions to the global anti-infective therapeutics landscape.

END